ALS drug will be pulled from Canada, U.S. markets after failed trial – National

Descrease article font size

Increase article font size

Amylyx Pharmaceuticals will withdraw its amyotrophic lateral sclerosis (ALS) drug – its only product in the market – from the U.S. and Canada after the treatment failed in a key late-stage trial.
The drugmaker on Thursday also announced a 70 per cent reduction in its workforce. It had 384 full-time employees at the end of 2023.The ALS drug, branded Relyvrio, was approved in 2022 after lobbying by patient groups who pointed to limited options to treat the potentially fatal disease. Story continues below advertisement

ALS causes progressive paralysis and death, and affects roughly 60,000 people in the U.S. and Europe.Approval followed a rare turnaround by the U.S. Food and Drug Administration’s advisers. They backed the drug months after rejecting it for a lack of “substantially persuasive” data.

Canadian researchers look at targeting inflammation as possible treatment for ALS

The approval was based on mid-stage trial data in 137 patients that showed the treatment slowed disease progression and extended life expectancy. Story continues below advertisement

However, a larger late-stage study failed to confirm the reported benefit of slowing disease progression, with no significant difference in patients treated with Relyvrio and placebo.

Trending Now

‘I would have never let him go’: Mother of boy killed by dogs in Edmonton shares grief

ABBA-versary: Fans mark 50 years since ‘Waterloo’ took the world by storm

The drug, which has a list price of  USD$158,000 per year in the U.S., generated sales of about $381 million in 2023.

The latest health and medical news
emailed to you every Sunday.

Amylyx expects to incur charges of about $19 million as part of its restructuring, expected to be completed by the end of the third quarter.Shares closed about 83 per cent lower and more than $1 billion was wiped out from its market value on March 8 after the company disclosed it was considering withdrawing the treatment.The company will advance trials of its lead experimental drug AMX0035 in inherited condition Wolfram syndrome and neurological disorder progressive supranuclear palsy. It will also focus on AMX0114 in ALS.


Explore more

Stop Letting Others Control Your Life

Stop Letting Others Control Your Life

SUMMARY: In this episode, Brendon teaches… How to focus more on positive life outcomes like life satisfaction, fitness, happiness, and confidence is essential. Why better embracing significant...

You Asked: In a Woman with ADHD, Should You Continue Treatment...

Question: I have a 32-year-old patient with ADHD who stopped her stimulant medication (Concerta 54 mg) during pregnancy. She is now at 34 weeks of...

The Future of Period Pain Relief

Hey there, womanhood warriors! We get you, and we especially get you on those days of the month. Period cramps are a real problem...
Preventive Care: How It Can Save Your Business Money On Health Insurance

Preventive Care: How It Can Save Your Business Money On Health...

As a small business owner in California or Arizona, you already understand the importance of keeping your employees healthy and productive. But you also...

Biosensor technology company Allez Health secures $60M

California-based Allez Health, formerly Zense-Life, announced it secured $60 million in Series A+ financing.  The round was led by strategic investor Osang Healthcare, with participation...
Omega-3 index test

Omega-3 index test and benefits for overall health and well-being

The Omega-3 Index test...
Thousands of NÜTRL tumblers recalled after dozens report illness - National

Thousands of NÜTRL tumblers recalled after dozens report illness – National

A promotional NÜTRL branded tumbler that was recalled in Canada earlier this month caused multiple reports of adverse health effects, an updated notice said...
Dentistry procurement platforms and trends 2024

E-Procurement Platforms, AI, and More Trends from DentalForum 2024

This article was written by the Planet DDS staff and originally published on this year’s DentalForum, leaders from more than two dozen dental...